Tuleviate: A Safer, Non-Addictive Analgesic

Potent Pain Relief Without the Risk of Addiction or Tolerance

Download One-Pager Download Slide Deck

Potent Pain Relief Without the Risk of Addiction or Tolerance

Tuleviate is a next-generation analgesic that selectively harnesses the body’s natural pain-relief pathways to deliver potent, long-lasting relief with a dramatically safer profile than traditional treatments. It is effective across a wide range of pain types, including acute, inflammatory, neuropathic, visceral, and postoperative pain.

Researchers

Why Tuleviate?

Potent, Long-Lasting Pain Relief

Effective across acute, inflammatory, neuropathic, visceral, and postoperative pain models.

Low Risk of Addiction

Demonstrates a non-addictive reward profile in preclinical models, unlike morphine or oxycodone.

Minimized Withdrawal and Relapse

Blocks withdrawal symptoms and prevents relapse in models of opioid dependency.

Reduced Tolerance Development

Maintains strong analgesic effects over time without the need for increasing doses.

Avoids Activation of CGRP and Glial Cells

In contrast to chronic morphine, does not induce these two major causes of opioid tolerance and persistent pain.

Safe and Well-Tolerated

Exhibits minimal respiratory depression, low toxicity, and a clean safety profile even at therapeutic doses.

Tuleviate provides significantly improved potency in visceral pain vs. morphine

Tuleviate does not induce drug-seeking behavior vs. morphine

Publications

Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice View
Endomorphin analog ZH853 shows low reward, tolerance, and affective-motivational signs of withdrawal, while inhibiting opioid withdrawal and seeking. View

Other resources

James Zadina Podcast Episode View
Title Country Date of Application Serial / ID Number Additional Notes
Tuleviate PCT US, Japan, Canada, Australia, and Hong Kong 07/08/2011 PCT/US2011/043306
Tuleviate EPO, US 05/01/2020 PCT/US20/31140 Method of use for treating opioid use disorder
Tuleviate NextGen (Glycosylated Analogs) Nationalized to US, AU, CA, JP, EPO 05/30/2023 PCT/US2023/23879 GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS
Tuleviate NextGen (Glycosylated Analogs) US 11/26/2024 18/869,591
Tuleviate NextGen (Glycosylated Analogs) Australia 12/19/2024 2023279699
Tuleviate NextGen (Glycosylated Analogs) Canada 11/27/2024 3,257,674
Tuleviate NextGen (Glycosylated Analogs) Japan 11/29/2024
Tuleviate NextGen (Glycosylated Analogs) EPO 12/19/2024 23816646.6

Funding Sources

Explore a Partnership

Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.

For inquiries, contact:
Alexis Ducote, PhD
Business Development Associate
aducote@tulane.edu
337.540.4025

X

Schedule a call

Set up a meeting with one of our team members by using the Calendly integration below.

Is it urgent? Call us:

James Zanewicz (+1 504.919.3800),

Alexis Ducote (+1 337.540.4025),

Carolyn Scofield (+1 504.881.4542).